NCT03660228View on ClinicalTrials.gov

Peri-Transfusion QOL Assessments (PTQA): A New Paradigm of Transfusion Decision Support for Patients With MDS

NACompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

October 17, 2018

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions
Myelodysplastic Syndromes
Interventions
OTHER

Peri-Transfusion QOL Assessment

Participants will undergo a peri-transfusion quality of life assessment (PTQA) using the Quality of Life in Myelodysplasia Scale (QUALMS)

Trial Locations (1)

02215

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Vera and Joseph Dresner Foundation

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT03660228 - Peri-Transfusion QOL Assessments (PTQA): A New Paradigm of Transfusion Decision Support for Patients With MDS | Biotech Hunter | Biotech Hunter